anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Composite materials that can be used to block ultraviolet radiation of a selected wavelength range are disclosed. The materials include dispersions of particles that exhibit optical resonance behavior, resulting in absorption cross-sections that substantially exceed the particles' geometric cross-sections. The particles are preferably manufactured as uniform nanosize encapsulated spheres, and dispersed evenly within a carrier material. Either the inner core or the outer shell of the particles comprises a conducting material exhibiting plasmon (Froehlich) resonance in a desired spectral band.  The large absorption cross-sections ensure that a relatively small volume of particles will render the composite material fully opaque (or nearly so) to incident radiation of the resonance wavelength, blocking harmful radiation.  The materials of the present invention can be used in manufacturing sunscreens, UV filters and blockers, ink, paints, lotions, gels, films, textiles, wound dressing and other solids having desired ultraviolet radiationabsorbing properties. The materials of the present invention can be used in systems consisting of reflecting substances such as paper or transparent support such as plastic or glass films. The particles can be further embedded in transparent plastic or glass beads to ensure a minimal distance between the particles.
Keep out of reach of children. Contains Sodium Metabisulfite, a sulfite that may cause serious allergic-type reactions, including anaphylactic symptoms (e.g., hives, itching) and life-threatening or less-severe asthmatic episodes in certain susceptible persons. For external use only. Avoid contact with the eyes. Some users may experience a mild skin irritation. If skin irritation becomes severe, stop use and consult a physician. Do not use on children under 12 years of age unless directed by a physician. If swallowed, get medical help or contact a poison control center right away.
Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
The invention relates to a thiazole pyridine compound and its preparation method. The compound is thiazolo(4,5-b)pyridine. The preparation method comprises the following steps: (1) a compound 13-bromine-2-aminopyridine is used as a starting material to react in the presence of benzoyl chloride and ammonium thiocyanate so as to obtain a benzoyl-protected thiourea-containing derivative compound 2; (2) the compound 2 undergoes hydrolysis to obtain a thiourea derivative compound; (3) the compound 3 undergoes ring closure under the action of NaH to generate a compound 4; and (4) the compound 4 undergoes deamination by the use of isoamyl nitrite to obtain a target product compound 5. According to the method, raw materials are cheap and easily available. The synthetic method is simple. The preparation method meets requirements of large-scale industrial production.
Before the application of TCT, complete transurethral bladder tumour resection (TURBT) was performed. RE-TURBT was conducted within 4 weeks for patients with initial T1 pathology. The first TCT instillation was applied at 1mo following the TURBT or the RE-TURBT.

Thermochemotherapy application and treatment schedule:

The bladder wall TCT (BWT) system (Elmedical Ltd, Hod-Hasharon, Israel) was used as a conductive heating modality. MMC (40 mg; MMC Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was mixed with 50 mL of 0.9% saline solution and applied using a disposable silicone 20Fr 3-way TCT catheter (UniThermia catheter; Elmedical Ltd). In each session, the bladder was irrigated with MMC solution at 42°C-45°C for 45 min via the BWT system. The treatment schedule consisted of an initial 6-week instillation, followed by control cystoscopy and urine cytology in the 3rd month and monthly instillations up to 1 yr. Urine cytology and cystoscopy were performed every three months. The samples were collected from the suspected areas during cystoscopy. At the end of the first year, control cystoscopy with random bladder biopsies was conducted. During the second year, routine controls were conducted every three months. Subsequently, follow-ups were performed every six months. In case of development of any complication in a patient, TCT was discontinued. Before each instillation of TCT, clear urine cultures were obtained from all patients. No prophylactic anticholinergic was administered prior to intravesical TCT. If TUR BT pathology was Ta or T1 during the follow-up, it was accepted as a recurrence. If it was CIS or T2, it was accepted as a progression. All adverse events observed during the study were recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 \[9. All study protocols were approved by the local ethical committee at our institution. An informed consent was obtained from all patients.
Atrial fibrillation (AF) is the most common cardiac rhythm disorder worldwide, and is gaining in prevalence. Currently, the treatment for atrial fibrillation is concentrated on patients with existing atrial fibrillation, and the reduction in risks of complications of stroke with anticoagulation. Furthermore, mechanical interventions such as atrial ablation procedures are fraught with inconsistent results. The availability of serum based biomarkers that can predict the early onset of atrial fibrillation, and also the ability to prognosticate risk, may help in the identification of patients at risk for AF complications early. This would also allow the identification of the patient population most suitable for the evaluation of possible future intervention strategies to prevent the onset of atrial fibrillation, and alter its natural history and complications.

Currently the best biomarkers in predicting atrial fibrillation risk are in fact markers for heart failure - NTproBNP and high sensitivity troponin. These markers are independent from CHA2DS2-VASc score. While this is very helpful, these markers will not be able to distinguish these 2 conditions because heart failure and atrial fibrillation often co-exist. The investigator's Cardiovascular Biomarker Discovery and Translation team has been using deep proteomic analysis of both human tissues and reprogrammed human stem cells to identify novel candidate biomarkers. This has been very successfully applied to diastolic heart failure, and there are now several new markers for this condition that have been validated across 3 populations. The investigators have several potential candidates for atrial fibrillation, but validation in the appropriate cohort, particularly those at the earliest risks of atrial fibrillation, will be most important.

The ARTESiA study is an ideal study setting to perform the biomarker validation, as the parent trial will recruit patients with silent atrial fibrillation detected only by dual-chamber pacemakers, defibrillators or insertable cardiac monitors. This would constitute a potentially earlier stage atrial fibrillation patient cohort, with known subsequent risks in a prospective fashion. The prospective evaluation of approved medications of aspirin and apixaban will also be helpful to determine if the prospective biomarker will be informative of the potential efficacy of treatment, or be unchanged by the treatment modalities.
PURPOSE:To obtain a vitamin D pharmaceutical, containing vitamin D and acid-soluble polymers, improved in stability of the vitamin D and preservable for a long period. CONSTITUTION:The objective substance is obtained by homogeneously mixing vitamin D (e.g. vitamin D2 or vitamin D3) with acid-soluble polymers (e.g. an aminoalkyl methacrylate copolymer B), as necessary, blending normally used pharmaceutical additives with the aforementioned ingredients and preparing a pharmaceutical according to a conventional method. The above-mentioned substance can be prepared into the form of powder, granule, granule for tableting, etc. The acid-soluble polymers are blended in an amount of >=1, especially 10-10000 times based on the vitamin D. Although the vitamin D is useful as a therapeutic agent for osteopathy such as rachitis or osteromalacia, it is unstable to heat and light and cannot be preserved for a long period even by preparation into the pharmaceutical. Thereby, the disadvantages are improved to prepare a stable vitamin D pharmaceutical.
BACKGROUND: The application of radiomics in thoracic lymph node metastasis (LNM) of lung adenocarcinoma is increasing, but diagnostic performance of radiomics from primary tumor to predict LNM has not been systematically reviewed. Therefore, this study sought to provide a general overview regarding the methodological quality and diagnostic performance of using radiomic approaches to predict the likelihood of LNM in lung adenocarcinoma.
METHODS: Studies were gathered from literature databases such as PubMed, Embase, the Web of Science Core Collection, and the Cochrane library. The Radiomic Quality Score (RQS) and the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) were both used to assess the quality of each study. The pooled sensitivity, specificity, and area under the curve (AUC) of the best radiomics models in the training and validation cohorts were calculated. Subgroup and meta-regression analyses were also conducted.
RESULTS: Seventeen studies with 159 to 1202 patients each were enrolled between the years of 2018 to 2022, of which ten studies had sufficient data for the quantitative evaluation. The percentage of RQS was between 11.1% and 44.4% and most of the studies were considered to have a low risk of bias and few applicability concerns in QUADAS-2. Pyradiomics and logistic regression analysis were the most commonly used software and methods for radiomics feature extraction and selection, respectively. In addition, the best prediction models in seventeen studies were mainly based on radiomics features combined with non-radiomics features (semantic features and/or clinical features). The pooled sensitivity, specificity, and AUC of the training cohorts were 0.84 (95% confidence interval (CI) [0.73-0.91]), 0.88 (95% CI [0.81-0.93]), and 0.93(95% CI [0.90-0.95]), respectively. For the validation cohorts, the pooled sensitivity, specificity, and AUC were 0.89 (95% CI [0.82-0.94]), 0.86 (95% CI [0.74-0.93]) and 0.94 (95% CI [0.91-0.96]), respectively.
CONCLUSIONS: Radiomic features based on the primary tumor have the potential to predict preoperative LNM of lung adenocarcinoma. However, radiomics workflow needs to be standardized to better promote the applicability of radiomics.
TRIAL REGISTRATION: CRD42022375712.
Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m\^2), 3 (325 mg/m\^2), and 5 (375 mg/m\^2) of course 1 and on day 1 (375 mg/m\^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m\^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
The purpose of the E-MECHANIC Trial is to test the effect of two doses of exercise on energy intake, body weight, body composition, activity levels, and metabolic rate. The exercise doses will reflect current recommendations for: 1) general health (8 KKW), and 2) weight loss (20 KKW). A non-exercise control group will also be recruited. The primary outcome variables are: 1) energy intake, and 2) the discrepancy between expected weight loss and observed weight loss. Energy intake will be measured using doubly labeled water and laboratory-based food intake tests. Secondary outcome variables include resting metabolic rate, activity levels (excluding structured exercise), and body composition. Following a comprehensive baseline assessment, participants will be randomly assigned to the 8 KKW, 20 KKW, or control group in a 1:1:1 ratio. Additional assessments will be conducted at week 4, with another comprehensive assessment at week 24. The week 4 assessment is important to determine if endpoints change in the short-term, but not long-term.
The incidence of colorectal cancer (CRC) is closely linked to metabolic diseases. Accumulating evidence suggests the regulatory role of AMP-activated protein kinase (AMPK) in cancer metabolic reprogramming. In this study, wild-type and AMPK knockout mice were subjected to azoxymethane-induced and dextran sulfate sodium (AOM/DSS)-promoted colitis-associated CRC induction. A stable AMPK-deficient Caco-2 cell line was also established for the mechanistic studies. The data showed that AMPK deficiency accelerated CRC development, characterized by increased tumor number, tumor size, and hyperplasia in AOM/DSS-treated mice. The aggravated colorectal tumorigenesis resulting from AMPK ablation was associated with reduced α-ketoglutarate production and ten-eleven translocation hydroxylase 2 (TET2) transcription, correlated with the reduced mismatch repair protein mutL homolog 1 (MLH1) protein. Furthermore, in AMPK-deficient Caco-2 cells, the mRNA expression of mismatch repair and tumor suppressor genes, intracellular α-ketoglutarate, and the protein level of TET2 were also downregulated. AMPK deficiency also increased hypermethylation in the CpG islands of Mlh1 in both colonic tissues and Caco-2 cells. In conclusion, AMPK deficiency leads to reduced α-ketoglutarate concentration and elevates the suppressive epigenetic modifications of tumor suppressor genes in gut epithelial cells, thereby increasing the risk of colorectal tumorigenesis. Given the modifiable nature of AMPK activity, it holds promise as a prospective molecular target for the prevention and treatment of CRC.
BACKGROUND: Susac's syndrome is an autoimmune angiopathy classically leading to the triad of encephalopathy, retinopathy and hearing loss. Multidisciplinarity is essential for diagnosis, which means in more detail a MRI-cerebrum, fluorescence angiography (FAG) and audiography. Early treatment is key since it is associated with better prognosis and reversibility.
CASE DESCRIPTION: This article presents a 71-year-old woman with multiple episodes of separate complaints (aphasia, behavioral changes, amnesia and vertigo with tinnitus). The MRI-cerebrum suspected Susac's syndrome with typical callosal lesions. An abnormal FAG and audiography completed the diagnostic triad of Susac's syndrome. Thereafter, treatment with immunosuppressants was initiated, which resulted in cognitive improvement.
FIELD: food, medical and mining industries. SUBSTANCE: MOS LENKIN is biologically active extract from mined ore containing curative rock wax known as "mumiyo". Mined ore is ground, extracted from water, subjected to decantation and filtering. Resulting extract is purified from heavy metals, concentrated and/or dried. Edible substance has specific chemical composition and can be used in food and medical industries. MOS LENKIN produces bioprotective effect namely: it normalizes metabolic processes, increases resistance of body to overloads, stimulates homopoietic system, exhibits antiinflammatory action, enhances immunity to various diseases, protects human organism against attack of various adverse factors, including radiation. EFFECT: higher efficiency.
Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
Clinical studies have not been conducted with HYCODAN in geriatric populations.

Use caution when considering the use of HYCODAN in patients 65 years of age or older. Elderly patients may have increased sensitivity to hydrocodone; greater frequency of decreased hepatic, renal, or cardiac function; or concomitant disease or other drug therapy [see Warnings and Precautions (5.4)].

Respiratory depression is the chief risk for elderly patients treated with opioids, including HYCODAN. Respiratory depression has occurred after large initial doses of opioids were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration [see Warnings and Precautions (5.4, 5.8)].

Hydrocodone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, monitor these patients closely for respiratory depression, sedation, and hypotension.
The relation relates to anthranilic acid amides, to a method for the production thereof, to their use as a medicament and to pharmaceutical preparations containing them. The compounds are therefore especially suited as antiarrhythmic active substances, particularly for treating and preventing atrial arrhythmias, e.g. atrial fibrillaion AF (atriale Fibrillation, AF) or atrial flutter (atriales Flattern). They act upon the Kv1.5 potassium channel and inhibit a potassium stream described as "ultra rapidly activated delayed rectifier" in the human cardiac atrium. The compounds have the formula wherein R1 to R 7 have the meaning given in the description. 15 claims
For the advancement of DKD treatment, identifying unrecognized residual risk factors is essential. We explored the impact of obesity diversity derived from different carbohydrate qualities, with an emphasis on the increasing trend of excessive fructose consumption and its effect on DKD progression. In this study, we utilized db/db mice to establish a novel diabetic model characterized by fructose overconsumption, aiming to uncover the underlying mechanisms of renal damage. Compared to the control diet group, the fructose-fed db/db mice exhibited more pronounced obesity yet demonstrated milder glucose intolerance. Plasma cystatin C levels were elevated in the fructose model compared to the control, and this elevation was accompanied by enhanced glomerular sclerosis, even though albuminuria levels and tubular lesions were comparable. Single-cell RNA sequencing of the whole kidney highlighted an increase in Lrg1 in glomerular endothelial cells (GECs) in the fructose model, which appeared to drive mesangial fibrosis through enhanced TGF-β1 signaling. Our findings suggest that excessive fructose intake exacerbates diabetic kidney disease progression, mediated by aberrant Lrg1-driven crosstalk between GECs and mesangial cells.
The present invention discloses a medicine for treating Mediterranean anemia and a preparing method thereof. The medicine is prepared by raw materials according to the following weight proportion: 6 to 12 portions of dogwood fruits, 4 to 10 portions of fleece-flower roots, 4 to 8 portions of prepared astragalua roots and 2 to 6 portions of donkey-hid gelatin. Clinical experiments of the medicine for treating beta-Mediterranean anemia diseases obtain the repeatable affirmative treatment effect. Besides, the obvious reduction of clinical symptoms and the reduction of circumferential hemogram are consistent. The present invention has the advantages of obvious increase (P<0.001) of hemoglobin (Hb), long holding time of treatment effect, and good after effect. The medicine treatment of beta-Mediterranean anemia can compensate beta-globin gene functional defects from different paths.
A method for isolating cells which have a suprabasal position and expresses epithelial specific antigen but no sialomucin is provided. The isolated cells are shown to share many of the properties expected of a mammary gland stem cell. Three permanent cell lines that are capable of proliferating and capable of differentiating into cells of mammary gland luminal epithelial and myoepithelial cell lineages were established. Such cells form elaborate branching structures resembling uncultured terminal duct lobular units both by morphology and marker expression both in vitro and in vivo. Evidence is provided that these keratin K19 expressing cells most probably is the cells in which breast cancer arises. Thus they constitute a model not only for the developing breast, but also for the development of breast cancer. Also disclosed are the uses of such isolated cells or the cell lines as a model system of the mammary gland for pharmacological studies and their uses in tissue repair or transplantation.
Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.
FIELD: medicine. SUBSTANCE: composition contains mixture of olive oil and parsley oil in ratio from 1 to 7, respectively. Besides, composition may comprise other vegetable oils, mint oil, menthol and chlorophyll. Said compositions may be in various forms including candies, chewing gum, tooth paste, liquid for oral gargle and pharmaceutical compositions, especially, in the form of soft gelatin capsules. For this purpose, they include proper additives and fillers introduced in the process of preparation of desired form. EFFECT: provision of clean and natural respiration during some hours, neutralization of unpleasant taste. 13 cl
The invention relates to the technical field of medicine, and particularly relates to a curcumin compound injection and an intravenous injection preparation thereof. The curcumin compound injection mainly comprises a curcumin compound, a solvent for injection and a small amount of pH regulator. The curcumin compound intravenous injection preparation is used only by mixing the curcumin compound injection and an emulsifier in a volume ratio of (1:5)-(1:250). After the curcumin compound injection and the emulsifier are mixed, the drug loading rate of the curcumin compound in the intravenous injection preparation is up to 1.5 mg/ml, and no crystal is separated out within 18 hours. The curcumin compound injection provided by the invention has a simple and safe preparation method and good stability, and is convenient for storage and transportation. The curcumin compound intravenous injection preparation has good stability due to the use of the emulsifier as a carrier solvent, and has no toxic and adverse effects. The invention solves the problem that the curcumin compound can not be prepared into the intravenous injection preparation and applied in clinics for a long period of time.